A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.
OBJECTIVE
To investigate the activity of carboplatin and cetuximab in NSCLC.


METHODS
This was a single arm, multicenter phase II trial, and the primary objective was response rate.


RESULTS
The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45).


CONCLUSIONS
The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.
Stinchcombe
Thomas E
TE
Multidisciplinary Thoracic Oncology Program at Lineberger Comprehensive Cancer Center at the University of North Carolina, Physicians Office Building, 3rd Floor 170 Manning Drive, Cb 7305, Chapel Hill, NC 27599-7305, USA. Thomas_Stinchcombe@med.unc.edu
Bradford
Daniel S
DS
Hensing
Thomas A
TA
LaRocca
Renato V
RV
Saleh
Mansoor
M
Evans
Tracey
T
Bakri
Kamal
K
Socinski
Mark A
MA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000068818:Cetuximab; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D000068818:Cetuximab